Delos Capital — Full Portfolio
36 tracked investments · listed companies and verified rows first
BiotechWaltham, US
JOSEPH FARMER(Executive Officer)PATRICK GERALD ENRIGHT(Director)HONGBO LU(Director)TOMAS KISELAK(Director)LEON O. MOULDER, JR.(Director)JOHN JACOB ORLOFF(Director)
Tulavi develops medical devices for peripheral nerve surgery, aiming to improve surgical treatment options and patient outcomes in nerve care.
HardwareHealthtechMedical DevicesMountain View, US
Corinne Bright(Executive Officer, Director)Farhad Khosravi(Executive Officer, Director)Fred Khosravi(Chairman & Co-Founder)Josh Vose(Chief Executive Officer)
BoardHenry Chen(Director)
Verge Medical (formerly Ostial Corporation) develops medical devices for aorto-ostial vascular interventions, including the FLASH Flex aorto-ostial angioplasty system and the RoVo mechanical thrombectomy device, used by physicians for coronary and peripheral vascular cases.
HealthtechMedical Devices
Mike Buck(Chief Executive Officer)Adam Tschida(General Manager & COO)
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Novel antiviral therapies with a lead program in HBV
Ablation catheter for the untreated atrial fibrillation market (acquired)
Atia Vision develops OmniVu, a modular shape-changing dual-optic intraocular lens (IOL) that uses the eye's natural accommodative mechanism to restore near, intermediate, and distance vision for cataract patients.
HardwareHealthtechMedical DevicesCampbell, US
Non-surgical, non-pharmacologic devices to induce weight loss
Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities.
BiotechHealthtech
Woburn, US
LAN BO CHEN(Executive Officer, Director)BRYAN KEANEY(Executive Officer)
BoardHENRY CHEN(Executive Officer, Director)
Curatia Medical develops, manufactures, and sells single-use interventional disposables for cardiac, peripheral, neuro, and pulmonary procedures, serving cardiovascular professionals and OEM customers.
Advanced ManufacturingHealthtechMedical DevicesSunnyvale, US
Boston, US
Innovations for vascular disease treatment including strokes and pulmonary embolisms
HealthtechCampbell, US
Matthew Garrett(Executive Officer)Charles Alpuche(Executive Officer)Scott Elliott(Executive Officer)Farhad Khosravi(Executive Officer, Director)Nick Hopkins(Director)
BoardJames Rogers(Director)
Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels.
BiotechHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Executive Officer)Raymond Lareau(Executive Officer)Steven Cagnetta(Executive Officer)Sean Boyle(Chief Executive Officer)
BoardHenry Chen(Director)Tasneem Dohadwala(Director)
Barricaid develops a bone-anchored implant designed to reduce reherniation and reoperation in patients undergoing discectomy for large annular defects.
HealthtechMedical DevicesWoburn, US
Gregory H. Lambrecht(Director)Brian Verrier(Director)Joshua Makower(Director)Carey Hagan(Executive Officer, Director)Kevin Sidow(Director)
BoardRyan Drant(Director)
Liposeuticals is a specialty pharmaceuticals company that reformulates sterile injectable drugs using a proprietary platform.
BiotechMedical Devices
Specialty pharma in dermatology and aesthetics for the Chinese market (acquired)
Phanes Therapeutics is a clinical-stage biotech company developing bispecific antibodies and other biologics for immuno-oncology, with three Phase 2 trials (spevatamig, peluntamig, mavrostobart).
BiotechDeep TechHealthtech
Hydrogel product to prevent intrauterine adhesions after uterine surgery
BiotechBedford, US
AMARPREET SAWHNEY(Executive Officer, Director, Promoter)NICK SVENCER(Executive Officer, Director, Promoter)FARHAD KHOSRAVI(Executive Officer, Director, Promoter)
BoardTARA BUTLER(Executive Officer, Director, Promoter)
Rgenta Therapeutics develops small molecule RNA modulation therapies through a discovery platform, aiming to create treatment options for patients with unmet medical needs across multiple therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Judith Li(Director)Debasish Roychowdhury(Director)Travis Wager(Co-founder, President and CSO)Sun Linghao(Director)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.